Description
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Atosiban Acetate Injection (Jiameidi®) |
| Generic Name | Atosiban Acetate |
| Synonyms | Tractocile, Antocin, Oxytocin Receptor Antagonist |
| CAS Number | 90779-69-4 |
| Formulation | Sterile aqueous injection |
| Strength | 6.75?mg in 0.9?mL vial |
| Pack Size | 1 vial per box |
| Dosage Form | Intravenous injection (research use only) |
| Approval Number | NMPA China: H20223013 |
| Product Code | 86979252000116 |
| Manufacturer | Hainan General Kangli Pharmaceutical Co., Ltd. |
| Barcode | 6930054180189 |
| Appearance | Clear, colorless, particle-free solution |
| Storage | Refrigerate at 2–8?°C; protect from light |
| Shelf Life | 2 years |
| Intended Use | Laboratory research only |
Mechanism of Action
Atosiban is a synthetic peptide oxytocin and vasopressin V1a receptor antagonist, rapidly inhibiting uterine contractions by blocking oxytocin-mediated calcium signaling in myometrial cells
Research Applications & Pharmacology
Used in tocolytic research to study delayed labor and uterine quiescence in vitro and in vivo models .
Explored for improving implantation rates in IVF through oxytocin receptor pathways .
Typical protocol: bolus IV dose of 6.75?mg followed by dosage adjustment based on model needs .
Safety Profile & Handling
Observed Effects:
No major side effects in preclinical studies; typical human effects: nausea, headaches .
Laboratory Handling:
Use full lab PPE (gloves, goggles, coat).
Store 2–8?°C; ensure visual clarity before use.
Dispose per biohazard/universal sharps regulations.
?? Research-Use Disclaimer
This product is exclusively for laboratory and preclinical research. It is not approved for therapeutic, diagnostic, clinical, or veterinary use. Misuse may pose safety risks and regulatory non-compliance.


Reviews
There are no reviews yet.